Pfizer Abandoning Indiplon Deal; Neurocrine Falls Again

A week after reporting that additional trials likely would be necessary for approval of its sleep drug, indiplon, Neurocrine Biosciences Inc. suffered another blow with the loss of its commercialization partner, Pfizer Inc. (BioWorld Today)